Significant weight loss and resultant malnutrition in patients undergoing radiotherapy for head and neck carcinomas are recognized and preventable clinical concerns. Morbidity related to weight loss during treatment may include dehydration, hospitalization, compromised treatment efficacy, and...

Amifostine is used as a radioprotectant in patients undergoing postoperative radiation therapy for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands to reduce or prevent acute or late xerostomia. Amifostine also is used in conjunction with...

Surgical treatment for head and neck cancer includes a variety of complex operative procedures. Patients scheduled for these operations often are presented with overwhelming amounts of information. Even after participating in the multi-disciplinary, preoperative teaching process, they may be unable...